Cantor Fitzgerald cut shares of PAVmed (NASDAQ:PAVM – Get Rating) from an overweight rating to a neutral rating in a research report released on Friday, The Fly reports. Cantor Fitzgerald currently has $1.50 price objective on the stock, down from their previous price objective of $4.00.
PAVM has been the topic of several other research reports. Lake Street Capital reduced their price target on shares of PAVmed from $5.00 to $1.50 and set a buy rating on the stock in a research note on Wednesday, January 18th. Ascendiant Capital Markets set a $8.25 target price on shares of PAVmed in a research report on Thursday, November 24th.
PAVmed Stock Down 0.7 %
PAVM stock opened at $0.46 on Friday. PAVmed has a 52 week low of $0.40 and a 52 week high of $2.34. The firm has a market capitalization of $41.49 million, a P/E ratio of -0.47 and a beta of 0.79. The company has a fifty day simple moving average of $0.61 and a two-hundred day simple moving average of $0.99.
Insider Buying and Selling at PAVmed
In other PAVmed news, Director Michael J. Glennon bought 62,000 shares of the business’s stock in a transaction on Monday, December 5th. The shares were acquired at an average price of $0.69 per share, with a total value of $42,780.00. Following the transaction, the director now owns 62,000 shares of the company’s stock, valued at approximately $42,780. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Michael J. Glennon bought 62,000 shares of the firm’s stock in a transaction that occurred on Monday, December 5th. The stock was bought at an average price of $0.69 per share, with a total value of $42,780.00. Following the completion of the transaction, the director now directly owns 62,000 shares of the company’s stock, valued at approximately $42,780. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael J. Glennon bought 100,000 shares of the stock in a transaction on Wednesday, December 7th. The stock was purchased at an average price of $0.62 per share, with a total value of $62,000.00. Following the completion of the purchase, the director now owns 250,000 shares of the company’s stock, valued at $155,000. The disclosure for this purchase can be found here. Insiders own 14.10% of the company’s stock.
Institutional Investors Weigh In On PAVmed
Institutional investors have recently bought and sold shares of the company. Pacific Wealth Management acquired a new stake in PAVmed in the second quarter valued at approximately $28,000. Private Advisor Group LLC boosted its stake in PAVmed by 40.8% in the first quarter. Private Advisor Group LLC now owns 31,823 shares of the company’s stock valued at $42,000 after acquiring an additional 9,215 shares in the last quarter. Guardian Wealth Advisors LLC acquired a new stake in shares of PAVmed during the third quarter worth $30,000. Glassman Wealth Services acquired a new stake in shares of PAVmed during the second quarter worth $33,000. Finally, UBS Group AG lifted its stake in shares of PAVmed by 777.9% during the third quarter. UBS Group AG now owns 41,200 shares of the company’s stock worth $35,000 after buying an additional 36,507 shares during the period. 13.98% of the stock is currently owned by institutional investors and hedge funds.
PAVmed, Inc is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes.
- Get a free copy of the StockNews.com research report on PAVmed (PAVM)
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.